导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.93% | 4058/4773 |
| 近一周 | -3.50% | 4249/5462 |
| 近一月 | -3.07% | 1541/5421 |
| 近一季 | -7.95% | 2604/5209 |
| 近半年 | -15.80% | 4017/4920 |
| 近一年 | -13.85% | 3623/4366 |
| 近两年 | 27.89% | 2371/2954 |
| 近三年 | 12.59% | 1681/2253 |
| 成立以来 | 36.36% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.81% 2918/4961 |
-15.37% 4661/5312 |
- - |
- - |
| 2025 | 29.00% 1431/4813 |
4.25% 970/3635 |
10.68% 237/4076 |
9.45% 3356/4524 |
2.14% 1070/4813 |
| 2024 | 7.90% 1608/3463 |
0.48% 963/2808 |
7.51% 86/3014 |
2.04% 2934/3129 |
-2.11% 1961/3463 |
| 2023 | -11.40% 1399/2656 |
-0.93% 1838/2280 |
-6.49% 1652/2385 |
-0.94% 470/2515 |
-3.45% 692/2655 |
| 2022 | -8.31% 154/2207 |
5.50% 33/1919 |
-0.80% 1655/2016 |
-21.31% 1901/2113 |
11.33% 146/2208 |
| 2021 | 23.98% 126/1822 |
15.05% 7/1255 |
1.07% 1069/1330 |
11.53% 110/1466 |
-4.40% 1481/1822 |
| 2020 | -10.20% 992/1250 |
-18.50% 1004/1028 |
5.51% 879/1067 |
-2.73% 1080/1164 |
7.37% 714/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 浙商中华预期高股息C VS. 长安沪深300非周期A(740101) |